Omnicell, Inc.
Financials
Valuation Metrics
Omnicell, Inc.'s Market Cap is $1.48B. At end of 2025 it was $2.04B. Ranked #2229 of 3,121 in US market (top 71%), #884 of 1,463 on NASDAQ (top 60%), #133 of 205 in Health Care Equipment & Services (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.48B | US#2,229/3,121 Sec#133/205 |
| Revenue | $1.25B | US#1,758/3,121 Sec#108/205 |
| Net Income | $39M | US#1,969/3,121 Sec#98/205 |
| Total Assets | $2.00B | US#2,085/3,121 Sec#105/205 |
| Net Assets | $1.29B | US#1,592/3,121 Sec#86/205 |
| Employees | 3,580 | US#1,403/3,121 Sec#99/205 |
| Value | ||
| P/E | 37.96x | US#1,765/3,121 Sec#81/205 |
| P/B | 1.15x | US#533/3,121 Sec#27/205 |
| PEG | 0.55x | US#639/3,121 Sec#27/205 |
| P/S | 1.19x | US#836/3,121 Sec#59/205 |
| EV/EBITDA | 13.12x | US#1,303/3,121 Sec#44/205 |
| FCF Yield | 9.53% | US#645/3,121 Sec#28/205 |
| Profitability | ||
| ROE | 3.03% | US#1,969/3,121 Sec#103/205 |
| ROA | 1.96% | US#1,660/3,121 Sec#103/205 |
| Op. Margin | 4.73% | US#2,015/3,121 Sec#108/205 |
| Revenue Growth | 8.45% | US#1,436/3,121 Sec#100/205 |
| Earnings Growth | 69.28% | US#396/3,121 Sec#16/205 |
| Financial Health | ||
| Debt Ratio | 54.76% | US#626/3,121 Sec#69/205 |
| Total Debt | $200M | US#2,252/3,121 Sec#124/205 |
| FCF | $141M | US#1,574/3,121 Sec#93/205 |
| Cash | $292M | US#1,440/3,121 Sec#82/205 |
| Current Ratio | 1.64x | US#1,518/3,121 Sec#135/205 |
| Net Debt/EBITDA | -0.87x | US#306/3,121 Sec#25/205 |
| Performance | ||
| 1Y Return | 4.62% | US#1,658/3,121 Sec#116/205 |
| 1M Return | -9.31% | US#2,367/3,121 Sec#164/205 |
| From 52W High | -40.69% | US#2,479/3,121 Sec#165/205 |
| 1Y MDD | -37.24% | US#1,872/3,121 Sec#105/205 |
| Trading | ||
| Volume | 353,255 shares | US#2,307/3,121 Sec#163/205 |
| Trading Value | $12M | US#2,256/3,121 Sec#150/205 |
| Per Share | ||
| EPS | $0.86 | US#1,726/3,121 Sec#92/205 |
| BPS | $28.40 | US#936/3,121 Sec#54/205 |
Company Info
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.